Doç. Dr. COŞKUN ÖZER DEMİRTAŞ

Yayın Ağı

Makaleler 35

1. Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective

Wong F., Adebayo D., George J., İDİLMAN R., Hayes P. C., Alvares-da-Silva M. R., et al.

Gut , 2026 (SCI-Expanded, Scopus)

2. BALAD-2 Emerges as the Most Accurate Prognostic Model in Hepatocellular Carcinoma: Results from a Biobank-Based Cohort Study

DEMİRTAŞ C. Ö., EREN F., YILMAZ KARADAĞ D., Kaldirim Armutcuoglu Y., Tolu T., Huseyinov J., et al.

Cancers , cilt.17, sa.21, 2025 (SCI-Expanded, Scopus)

3. Enhancing Hepatocellular Carcinoma Surveillance: Comparative Evaluation of AFP, AFP-L3, DCP and Composite Models in a Biobank-Based Case-Control Study

DEMİRTAŞ C. Ö., AKIN Ş., YILMAZ KARADAĞ D., YILMAZ İ. T., Ciftci U., Huseynov J., et al.

Cancers , cilt.17, sa.14, 2025 (SCI-Expanded, Scopus)

4. Usefulness of Endoscopic Ultrasound Strain Elastography for Measuring Liver Stiffness and the Role of Blood Cytokeratin 18 Levels as a Surrogate Marker of Fibrosis

Duman D. G., Alahdab Y. O., DEMİRTAŞ C. Ö., YILMAZ Y., DİLBER F., Ozdemir F. T., et al.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.36, sa.10, ss.692-699, 2025 (SCI-Expanded, Scopus, TRDizin)

5. A rare clinic in hepatocellular cancer: Metastasis of the nasopharynx

Ozturk F. E., DEMİRTAŞ C. Ö., Jafarov F., Keskin Ozturk B., Dilber F.

Hepatology Forum , cilt.6, sa.2, ss.62-64, 2025 (Scopus, TRDizin)

6. Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy study

Ergenc I., Kara E., Yilmaz M. E., Demirtaş C. Ö., Keklikkiran C., Das T., et al.

Heliyon , cilt.10, sa.15, 2024 (SCI-Expanded, Scopus)

7. The preliminary data of gene expressions and bioinformatics analysis of miR-146b-5p and miR-4510 in Turkish population in HBV related hepatocellular carcinoma

BİRCAN KADIOĞLU D., DEMİRTAŞ C. Ö., PİRİM D., Gündüz F., EREN F.

Hepatology forum , cilt.5, ss.106-112, 2024 (ESCI, Scopus, TRDizin)

8. Decoding 17-Beta-hydroxysteroid Dehydrogenase 13: A Multifaceted Perspective on Its Role in Hepatic Steatosis and Associated Disorders

DEMİRTAŞ C. Ö., YILMAZ Y.

Journal of Clinical and Translational Hepatology , cilt.12, sa.10, ss.857-864, 2024 (SCI-Expanded, Scopus)

9. Radiological Quantification of Sarcopenic Obesity and its Role in Chronic Liver Disease Severity.

Cimsit C., Kursun M., Demircioglu O., Dilber F., Demirtas C. O., Ergenc I.

Academic radiology , cilt.30, 2023 (SCI-Expanded)

10. Evaluation of the effectiveness of drug-eluting transarterial chemoebolization in hepatocellular carcinoma

ALAN A. M., ALAN Ö., ASADOV R., DEMİRTAŞ C. Ö., KANİ H. T., YUMUK P. F., et al.

Hepatology forum , cilt.4, sa.2, ss.53-60, 2023 (Scopus, TRDizin)

11. Practicality and potential restrictions of unresectable hepatocellular carcinoma prognostic index

DEMİRTAŞ C. Ö., Ricco G., ÖZDOĞAN O. C., BALTACIOĞLU F., ÖNEŞ T., YUMUK P. F., et al.

HEPATOLOGY COMMUNICATIONS , cilt.6, sa.12, ss.3600-3601, 2022 (SCI-Expanded)

12. Characteristics of patients with hepatocellular carcinoma: A multicenter study

Guzelbulut F., KARAOĞULLARINDAN Ü., AKKIZ H., ALTINTAŞ E., DEMİRTAŞ C. Ö., Bahadir O., et al.

HEPATOLOGY FORUM , cilt.3, sa.3, ss.71-76, 2022 (ESCI)

13. Preliminary results of the effectiveness and safety of Tenofovir Alefenamide Fumarate prophylaxis in HBV-infected individuals, who received chemo/immunosuppressive therapy

GÜNDÜZ F., DURAK S., ÜNSAL Y., DEMİR M., Ellik Z. M., YILDIRIM A. E., et al.

JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded)

14. Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders

DEMİRTAŞ C. Ö., Ricco G., ÖZDOĞAN O. C., BALTACIOĞLU F., Ones T., YUMUK P. F., et al.

HEPATOLOGY COMMUNICATIONS , cilt.6, sa.3, ss.633-645, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

15. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?

Fulgenzi C. A. M., D'Alessio A., Ogunbiyi O., DEMİRTAŞ C. Ö., Gennari A., Cortellini A., et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS , cilt.31, ss.681-691, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

16. Surveillance Strategies for Hepatocellular Carcinoma: Recent Advances and the Shifting Paradigm

DEMİRTAŞ C. Ö., GÜNDÜZ F., ÖZDOĞAN O. C.

JOURNAL OF GASTROINTESTINAL CANCER , cilt.52, sa.4, ss.1336-1339, 2021 (ESCI) Sürdürülebilir Kalkınma

17. Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story

DEMİRTAŞ C. Ö., GÜNDÜZ F.

JOURNAL OF GASTROINTESTINAL CANCER , cilt.52, sa.4, ss.1217-1222, 2021 (ESCI)

18. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma

DEMİRTAŞ C. Ö., 'Alessio A., Rimassa L., Sharma R., Pinato D. J.

JHEP REPORTS , cilt.3, sa.5, 2021 (ESCI) Sürdürülebilir Kalkınma

19. Impact of COVID-19 Pandemic on Gastroenterology Fellowship Training in Turkey: A Prospective Nationwide Survey Study

DEMİRTAŞ C. Ö., Vahabov C., Mustafayev F., Sahin T., PARLAK E.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.10, ss.879-891, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

20. MODELLING THE DYNAMICS OF CANCER CELLS AND TUMOR VASCULATURE IN HCC PATIENTS TREATED WITH TKIs OR TACE

Colombatto P., Damone F., Ricco G., Oliveri F., Civitano L., Romagnoli V., et al.

HEPATOLOGY , cilt.74, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

21. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?

DEMİRTAŞ C. Ö., Brunetto M. R.

WORLD JOURNAL OF GASTROENTEROLOGY , cilt.27, sa.33, ss.5536-5554, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

22. Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease

KANİ H. T., DEMİRTAŞ C. Ö., KEKLİKKIRAN Ç., Ergenc I., Mehdiyev S., AKDENİZ E., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.8, ss.661-666, 2021 (SCI-Expanded)

23. Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study

DEMİRTAŞ C. Ö., Tolu T., KEKLİKKIRAN Ç., ÖZDOĞAN O. C., GÜNDÜZ F.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.8, ss.685-693, 2021 (SCI-Expanded)

24. Proposal and validation of a novel scoring system for hepatocellular carcinomas beyond curability borders: Unresectable hepatocellular carcinoma prognostic index

DEMİRTAŞ C. Ö., Ricco G., ÖZDOĞAN O. C., BALTACIOĞLU F., ÖNEŞ T., YUMUK P. F., et al.

JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded)

25. Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib

Colombatto P., DEMİRTAŞ C. Ö., Ricco G., Civitano L., Boraschi P., Scalise P., et al.

CANCERS , cilt.13, sa.9, 2021 (SCI-Expanded)

26. The natural course of gastric intestinal metaplasia in Turkish patients: A single-center observational cohort study

DEMİRTAŞ C. Ö., Koldas M., Yilmaz M., Sahin M. Z., Soykuvvet M. T., ÇELİKEL Ç., et al.

MARMARA MEDICAL JOURNAL , cilt.34, sa.3, ss.229-233, 2021 (ESCI) Sürdürülebilir Kalkınma

27. Letter: Is female sex an independent predictor of favourable prognosis in hepatocellular carcinoma?

Demirtas C. O., Gunduz F.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.52, ss.1765-1766, 2020 (SCI-Expanded)

28. Myeloperoxidase and calprotectin; Any role as non-invasive markers for the prediction of inflammation and fibrosis in non-alcoholic steatohepatitis?

Bicakci E., DEMİRTAŞ C. Ö., ÇELİKEL Ç., HAKLAR G., DUMAN D.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.31, sa.10, ss.681-687, 2020 (SCI-Expanded, Scopus, TRDizin)

29. Surveillance of hepatocellular carcinoma in cirrhotic patients: Current knowledge and future directions

Demirtas C. O., ÖZDOĞAN O. C.

HEPATOLOGY FORUM , cilt.1, sa.3, ss.112-118, 2020 (ESCI)

30. The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance

DEMİRTAŞ C. Ö., SAPMAZ A., GÜREL B. A., KIZMAZ H., ULU T., KARAKETİR Ş. G., et al.

Hepatology Forum , cilt.1, sa.3, ss.101-108, 2020 (Hakemli Dergi) Sürdürülebilir Kalkınma

31. Metabolic-associated Fatty Liver Disease: Time to integrate ground-breaking new terminology to our clinical practice?

DEMİRTAŞ C. Ö., YILMAZ Y.

Hepatology Forum , cilt.1, sa.3, ss.79-81, 2020 (Hakemli Dergi)

32. Validation and reliability of the Turkish version of the inflammatory bowel disease questionnaire for ulcerative colitis and Crohn's disease

KANİ H. T., Ergenc I., Arikan H., Komesli Z., Seyrek B., DEMİRTAŞ C. Ö., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.31, sa.8, ss.566-572, 2020 (SCI-Expanded)

33. A large Turkish pedigree with multiple endocrine neoplasia type 1 syndrome carrying a rare mutation: c.1680_1683 del TGAG

Demirtaş C. Ö., Ata P., Çetin A., Turkyilmaz A., Duman D.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.31, ss.508-514, 2020 (SCI-Expanded)

34. The optimal controlled attenuation parameter cut-offs in hepaticsteatosis grade differentiation by transient elastography(Fibroscan) in a sample of biopsy-proven non-alcoholic fatty liverdisease patients

Kaya E., BAKIR A., Sapmaz A. F., Kayyali T., Quatranji L., Çiftaslan A., et al.

Hepatology International , cilt.13, ss.196, 2019 (SCI-Expanded, Scopus)

35. Convenient chronic hepatitis B candidates for antiviral cessation and retreatment after relapse: When and who?

DEMİRTAŞ C. Ö., ÖZDOĞAN O. C.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.29, sa.6, ss.720-721, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 5

1. Sirotik Hastalarda Portal Hipertansif Gastropatinin Prevalansı ve Prediktif Değerlerinin İncelenmesi

MAMMADOVA A., TAZEGÜL G., DEMİRTAŞ C. Ö., ATUĞ Ö., ÖZDOĞAN O. C.

42. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 25 - 30 Kasım 2025, (Özet Bildiri)

2. “The gene expressions and bioinformatics analysis of miR-146b-5p and miR-4510 in Hepatocellular Carcinoma”

BİRCAN KADIOĞLU D., DEMİRTAŞ C. Ö., PİRİM D., Gündüz F., EREN F.

EASL Liver Cancer Summit, Estoril, Portekiz, 20 Nisan 2023, ss.134-135, (Özet Bildiri)

3. USEFULNESS OF ENDOSCOPIC ULTRASONOGRAPHY ELASTOGRAPHY (EUS-E) TO MEASURE LIVER STIFFNESS

Duman D. G., Alahdab Y., Demirtas C. O., YILMAZ Y., GÜNDÜZ F.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)

4. ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY

Bilgin B. O., SÜNBÜL M., Kani H. T., Demirtas C. O., KEKLİKKIRAN Ç., YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)

5. Annual contrast-enhanced MRI is highly effective in the surveillance of hepatocellular carcinoma in cirrhotic patients

DEMİRTAŞ C. Ö., GÜNDÜZ F., TÜNEY D., BALTACIOĞLU F., ÖZEN ALAHDAB Y., ÖZDOĞAN O. C.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri)

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler